[Do biologicals have a place in the treatment of collagen diseases? Pro].
Lorenz
H-M
HM
Abteilung Innere Medizin V, Medizinische Universitätsklinik Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg. Hannes.Lorenz@med.uni-heidelberg.de
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001688:Biological Products / Q000627:therapeutic use*; D003095:Collagen Diseases / Q000188:drug therapy*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D000069285:Infliximab; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D001688:Biological Products; D007155:Immunologic Factors; D000069283:Rituximab; D000069285:Infliximab; C502936:tocilizumab